PolyPid Ltd expected to post a loss of 55 cents a share - Earnings Preview
11/08/2025 14:13
PolyPid Ltd PYPD.OQ PYPD.O is expected to show no change in quarterly revenue when it reports results on August 13 for the period ending June 30 2025 LSEG's mean analyst estimate for PolyPid Ltd is for a loss of 55 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for PolyPid Ltd is $13.50, about 76.1% above its last closing price of $3.22 Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Mar. 31 2025 | -0.82 | -0.80 | -0.70 | Beat | 12.1 |
| Dec. 31 2025 | -0.82 | -0.88 | -1.09 | Missed | -24.4 |
| Sep. 30 2024 | -0.96 | -1.00 | -1.22 | Missed | -21.8 |
| Jun. 30 2024 | -1.30 | -1.30 | -1.25 | Beat | 3.7 |
| Mar. 31 2024 | -1.42 | -1.41 | -1.37 | Beat | 3 |
| Dec. 31 2023 | -3.18 | -3.58 | -3.97 | Missed | -10.7 |
| Sep. 30 2023 | -3.99 | -4.16 | -3.40 | Beat | 18.3 |
| Jun. 30 2023 | -6.90 | -9.18 | -3.90 | Beat | 57.5 |
Recent news on Polypid
See all newsPolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary
PolyPid Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA